Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety and tolerability and determine a recommended
Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced
solid tumors for which bevacizumab is indicated.